Navigation Links
Serica Technologies Receives ISO Certification, Meets International Standards for Medical Device Manufacturing
Date:11/19/2008

h the confidence demonstrated by our investors, particularly in this challenging economic environment, this additional funding provides Serica with a very strong financial position to execute on our commercialization plan for the SeriACL in Europe, and to continue our clinical program to gain approval in the U.S. market," said Altman.

Serica is also moving forward with expanding its clinical, engineering and scientific teams, as part of the company's strategic growth plan. "We have added significant depth in both R&D and quality affairs, and have expanded our staff in other key areas, in our planned approach to prepare for commercialization," Altman added. "We now have 35 employees, including an exceptional team of research, regulatory, manufacturing and business professionals, with additional hiring planned in 2009."

About Serica's Biomaterials

The body's structural tissue can be destroyed, removed or weakened due to trauma, disease or aging. Serica is developing natural, silk biomaterials designed to act as "scaffolds" to provide support and relief to damaged tissues, in order to promote restored function. The company's ligament grafts for ACL repair, surgical meshes and gels, are comprised of the fiber protein of the B. mori silkworm, which has centuries of human use. In pre-clinical studies, Serica's silk-based products are shown to be bioresorbed at slower rates than other common structural proteins, such as collagen, to enable optimal healing. Its products require no re-hydration or advance preparation for surgical implantation.

Serica is developing products for a wide variety of applications where current materials fail to meet the needs of clinicians and patients, including connective tissue repair of the knee, shoulder, abdomen, breast, neck and face.

About Serica Technologies Inc.

Serica Technologies, Inc., formerly Tissue Regeneration, Inc., i
'/>"/>

SOURCE Serica Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
3. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
4. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
5. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
6. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
7. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
8. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
11. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
Post Your Comments:
*Name:
*Comment:
*Email: